KYOWA KIRIN CO. LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,630 JPY | +0.23% |
|
+0.80% | +10.97% |
| Apr. 08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
| Apr. 03 | Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March | MT |
ETFs positioned on Kyowa Kirin Co. Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.22% | 15 M€ | +7.34% | ||
| 0.44% | 11 M€ | +10.37% | - | |
| 0.41% | 251 M€ | +13.17% | ||
| 0.39% | 31,732 M€ | +14.31% | - | |
| 0.39% | 1,198 M€ | +13.48% | - | |
| 0.36% | 67,864 M€ | +14.28% | ||
| 0.36% | 16,729 M€ | +13.38% | - | |
| 0.30% | 26 M€ | +20.62% | ||
| 0.27% | 4 M€ | +13.95% | ||
| 0.27% | 81 M€ | +14.05% | ||
| 0.26% | 73 M€ | +11.61% | ||
| 0.23% | 60 M€ | +14.42% | ||
| 0.17% | 5,115 M€ | +13.58% | ||
| 0.17% | 10,207 M€ | +14.32% | ||
| 0.15% | 18 M€ | +16.15% | - | |
| 0.15% | 5 M€ | +10.09% | - | |
| 0.15% | 14 M€ | +5.66% | - | |
| 0.15% | 14 M€ | +15.63% | ||
| 0.13% | 20,721 M€ | +13.52% | - | |
| 0.13% | 144,586 M€ | +14.49% | ||
| 0.13% | 66,066 M€ | +14.68% | - | |
| 0.12% | 29 M€ | +8.37% | - | |
| 0.10% | 469 M€ | -2.05% | - | |
| 0.10% | 3,859 M€ | +18.82% | - | |
| 0.09% | 4 M€ | -.--% | - | |
| 0.03% | 7 M€ | +0.11% | - | |
| 0.03% | 10 M€ | -3.35% | - | |
| 0.03% | 7 M€ | +1.95% | - | |
| 0.02% | 277 M€ | -.--% | - |
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,630
JPY
Average target price
3,067
JPY
Spread / Average Target
+16.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.97% | 8.94B | |
| +5.31% | 70.44B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 4151 Stock
- Funds and ETFs Kyowa Kirin Co. Ltd.
